FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283775462> ?p ?o ?g. }

• W4283775462 endingPage "S260" @default.
• W4283775462 startingPage "S259" @default.
• W4283775462 abstract "Approximately 8 - 10% of metastatic colorectal cancers (mCRC) have a BRAF V600E mutation. BRAF V600E mutant mCRC represents a distinct clinical subset with a poor prognosis. Previous treatment guidelines have been derived from subgroup analyses of non-designated BRAF V600E trials. Real world studies have shown that outcomes and treatment practices can vary widely. Here, we report on our regional practices and outcomes. We undertook a retrospective analysis of all mCRC patients with confirmed BRAF V600E mCRC diagnosed in NHS Greater Glasgow and Clyde Health Board (Scotland, UK) between 01/01/2015 - 31/12/2020. Clinical and pathological features were obtained from electronic records. Univariate analysis of prognostic factors was performed using Kaplan Meier analysis and log-rank test. Multivariate analysis was performed using Cox regression. A total of 139 patients were identified for study with 1 excluded for missing follow up information. Median age at metastatic diagnosis was 69 years, with a female preponderance (59% female, 41% male). 31% of tumours also had deficient mismatch repair (dMMR) or high levels of microsatellite instability (MSI-H). Primary tumour site was mostly right-sided (n=102, 74%), with less left-sided (n=20, 15%) and rectal (n=15, 11%) tumours. 1 patient had 2 synchronous primaries (1 right colon and 1 rectal). 64% presented with de novo metastatic disease. For those with initial loco-regional disease, the median time to metastatic progression was 10 months. The most common metastatic sites were liver (54%), peritoneal (33%), lymph node (31%), and lung (28%). 36% of patients did not receive any systemic treatment, 36% received 1 line, and 28% received 2 or more lines of treatment. Most (69%) received a cytotoxic chemotherapy doublet as first-line treatment, and 6% received triplet cytotoxic chemotherapy. 7% received immunotherapy. Among the treated patients, only 19% received some form of targeted therapy over their full treatment course, usually a combination containing an anti-EGFR inhibitor. The median overall survival was poor at 7.2 months. Features significantly associated with shorter survival were performance status (PS) of 2 or worse (p < 0.01), the presence of lymph node metastasis (p = 0.010) and peritoneal metastasis (p < 0.01), a higher modified Glasgow Prognostic Score (GPS) of 2 (p = 0.035) and a high neutrophil-lymphocyte ratio >5 (p = 0.032). Primary tumour site was also significantly associated with survival (p < 0.01), with worse survival for right-sided tumours (6.6 months), compared to 14.0 months for left-sided/rectal tumours. Using multivariate analysis, independent prognostic markers were PS, presence of lymph node metastasis, presence of peritoneal metastasis and right-sided primary tumour location. This is a representative cohort of BRAF V600E metastatic colorectal cancer patients, which confirms previously known clinical features. Of the common metastatic sites, peritoneal or lymph node metastases confer a poorer prognosis. There was not widespread adoption of more intensive triplet chemotherapy over the study time period. Overall survival is poor, and changed treatment strategies facilitated by recent clinical trial advances with targeted therapies may improve outcomes in this poor prognostic group." @default.
• W4283775462 created "2022-07-03" @default.
• W4283775462 creator A5017977044 @default.
• W4283775462 creator A5021851834 @default.
• W4283775462 creator A5024698584 @default.
• W4283775462 creator A5037706808 @default.
• W4283775462 creator A5043093280 @default.
• W4283775462 creator A5051566136 @default.
• W4283775462 creator A5056943821 @default.
• W4283775462 creator A5060527528 @default.
• W4283775462 date "2022-06-01" @default.
• W4283775462 modified "2023-10-01" @default.
• W4283775462 title "P-36 Real-world outcomes in BRAFV600E metastatic colorectal cancer – the Glasgow experience" @default.
• W4283775462 doi "https://doi.org/10.1016/j.annonc.2022.04.127" @default.
• W4283775462 hasPublicationYear "2022" @default.
• W4283775462 type Work @default.
• W4283775462 citedByCount "0" @default.
• W4283775462 crossrefType "journal-article" @default.
• W4283775462 hasAuthorship W4283775462A5017977044 @default.
• W4283775462 hasAuthorship W4283775462A5021851834 @default.
• W4283775462 hasAuthorship W4283775462A5024698584 @default.
• W4283775462 hasAuthorship W4283775462A5037706808 @default.
• W4283775462 hasAuthorship W4283775462A5043093280 @default.
• W4283775462 hasAuthorship W4283775462A5051566136 @default.
• W4283775462 hasAuthorship W4283775462A5056943821 @default.
• W4283775462 hasAuthorship W4283775462A5060527528 @default.
• W4283775462 hasBestOaLocation W42837754621 @default.
• W4283775462 hasConcept C104317684 @default.
• W4283775462 hasConcept C121608353 @default.
• W4283775462 hasConcept C126322002 @default.
• W4283775462 hasConcept C143998085 @default.
• W4283775462 hasConcept C144301174 @default.
• W4283775462 hasConcept C180754005 @default.
• W4283775462 hasConcept C185592680 @default.
• W4283775462 hasConcept C2779767149 @default.
• W4283775462 hasConcept C38180746 @default.
• W4283775462 hasConcept C50382708 @default.
• W4283775462 hasConcept C526805850 @default.
• W4283775462 hasConcept C55493867 @default.
• W4283775462 hasConcept C61320498 @default.
• W4283775462 hasConcept C66339696 @default.
• W4283775462 hasConcept C71924100 @default.
• W4283775462 hasConceptScore W4283775462C104317684 @default.
• W4283775462 hasConceptScore W4283775462C121608353 @default.
• W4283775462 hasConceptScore W4283775462C126322002 @default.
• W4283775462 hasConceptScore W4283775462C143998085 @default.
• W4283775462 hasConceptScore W4283775462C144301174 @default.
• W4283775462 hasConceptScore W4283775462C180754005 @default.
• W4283775462 hasConceptScore W4283775462C185592680 @default.
• W4283775462 hasConceptScore W4283775462C2779767149 @default.
• W4283775462 hasConceptScore W4283775462C38180746 @default.
• W4283775462 hasConceptScore W4283775462C50382708 @default.
• W4283775462 hasConceptScore W4283775462C526805850 @default.
• W4283775462 hasConceptScore W4283775462C55493867 @default.
• W4283775462 hasConceptScore W4283775462C61320498 @default.
• W4283775462 hasConceptScore W4283775462C66339696 @default.
• W4283775462 hasConceptScore W4283775462C71924100 @default.
• W4283775462 hasLocation W42837754621 @default.
• W4283775462 hasOpenAccess W4283775462 @default.
• W4283775462 hasPrimaryLocation W42837754621 @default.
• W4283775462 hasRelatedWork W1998259048 @default.
• W4283775462 hasRelatedWork W2361700749 @default.
• W4283775462 hasRelatedWork W2375628929 @default.
• W4283775462 hasRelatedWork W2384514534 @default.
• W4283775462 hasRelatedWork W2386134303 @default.
• W4283775462 hasRelatedWork W2405817813 @default.
• W4283775462 hasRelatedWork W2944348386 @default.
• W4283775462 hasRelatedWork W3022070425 @default.
• W4283775462 hasRelatedWork W3141065388 @default.
• W4283775462 hasRelatedWork W4361918880 @default.
• W4283775462 hasVolume "33" @default.
• W4283775462 isParatext "false" @default.
• W4283775462 isRetracted "false" @default.
• W4283775462 workType "article" @default.